Literature DB >> 15980894

Conjugation of tetanus toxoid with Salmonella typhimurium PTCC 1735 O-specific polysaccharide and its effects on production of opsonizing antibodies in a mouse model.

Nima Hosseini Jazani1, Elizabeth Worobec, Shahram Shahabi, Ghorban Behzadian Nejad.   

Abstract

Serious enteric and extra-intestinal infections with Salmonella typhimurium are very common in many human populations. Phagocytosis is the main defense mechanism against this bacterium; however, the unique structure of S. typhimurium lipopolysaccharide (LPS) makes it resistant to opsonization by complement components. In the present study, the S. typhimurium LPS O-chain was purified and conjugated with tetanus toxoid and the effects of the conjugated vaccine (O-specific polysaccharide tetanus toxoid (O-SP-TT)) on induction of specific antibodies were investigated in a mouse model. In vitro assays measuring phagocytosis in the presence of opsonizing antibodies were performed. Three subcutaneous injections of the O-SP-TT conjugate conferred protection against the intraperitoneal challenge with S. typhimurium and the LD50 was greater for immunized animals than for controls. The mean number of ingested S. typhimirium / mouse peritoneal cell in the presence of sera obtained from immunized mice with purified O-chain, O-SP-TT conjugate, heat-killed bacteria, and negative control were 6.96, 14.24, 15.96, and 6.67, respectively. In summary, we developed an O-SP-TT conjugate that induced opsonizing antibodies that increased phagocytosis, as determined by in vitro assays. In addition, chemiluminescence results, an indicator of oxidative burst, indicated that peritoneal cells respond better to live S. typhimurium cells in the presence of sera obtained from O-SP-TT conjugate immunized mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980894     DOI: 10.1139/w05-008

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  5 in total

Review 1.  Mouse models to assess the efficacy of non-typhoidal Salmonella vaccines: revisiting the role of host innate susceptibility and routes of challenge.

Authors:  Raphael Simon; Sharon M Tennant; James E Galen; Myron M Levine
Journal:  Vaccine       Date:  2011-05-25       Impact factor: 3.641

2.  Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar Typhimurium.

Authors:  S Rondini; F Micoli; L Lanzilao; M Gavini; R Alfini; C Brandt; S Clare; P Mastroeni; A Saul; C A MacLennan
Journal:  Infect Immun       Date:  2014-12-29       Impact factor: 3.441

3.  Gp96 rich lysate as a vaccine candidate against infection with Salmonella typhimurium.

Authors:  N Hosseini Jazani; M Karimzad; S Shahabi
Journal:  Iran J Microbiol       Date:  2010-12

4.  A Highly Effective Component Vaccine against Nontyphoidal Salmonella enterica Infections.

Authors:  Rosana B R Ferreira; Yanet Valdez; Brian K Coombes; Subash Sad; Joost W Gouw; Eric M Brown; Yuling Li; Guntram A Grassl; L Caetano M Antunes; Navkiran Gill; Mimi Truong; Roland Scholz; Lisa A Reynolds; Laskshmi Krishnan; Ahmed A Zafer; Neta Sal-Man; Michael J Lowden; Sigrid D Auweter; Leonard J Foster; B Brett Finlay
Journal:  MBio       Date:  2015-09-22       Impact factor: 7.867

5.  Development of ELISAs for diagnosis of acute typhoid fever in Nigerian children.

Authors:  Jiin Felgner; Aarti Jain; Rie Nakajima; Li Liang; Algis Jasinskas; Eduardo Gotuzzo; Joseph M Vinetz; Fabio Miyajima; Munir Pirmohamed; Fatimah Hassan-Hanga; Dominic Umoru; Binta Wudil Jibir; Safiya Gambo; Kudirat Olateju; Philip L Felgner; Stephen Obaro; D Huw Davies
Journal:  PLoS Negl Trop Dis       Date:  2017-06-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.